Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405239 | 1.00 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBRAPGEF3 | |
| SCHEMBL29911230 | 0.88 | — | — | |
| SCHEMBL23429993 | 0.88 | — | — | |
| SCHEMBL23405284 | 0.88 | — | — | |
| SCHEMBL22521454 | 0.82 | PRMT5 (0.42) | RAPGEF3PRMT5 | |
| SCHEMBL21061719 | 0.82 | PRMT5 (0.42) | RAPGEF3PRMT5 | |
| SCHEMBL23430012 | 0.82 | PRMT5 (0.42) | RAPGEF3PRMT5 | |
| SCHEMBL29522691 | 0.82 | PRMT5 (0.42) | RAPGEF3PRMT5 | |
| SCHEMBL23429861 | 0.78 | HRH2 (0.30) | — | |
| SCHEMBL23405183 | 0.78 | HRH2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163486-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163486-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PI4KA 3842/4885PI4K2B 3728/4885PI4K2A 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.